The Effects of a Perindopril-Based Regimen in Relation to Statin Use on the Outcomes of Patients with Vascular Disease: a Combined Analysis of the ADVANCE, EUROPA, and PROGRESS Trials

Purpose To study the effects of a perindopril-based regimen on cardiovascular (CV) outcomes in patients with vascular disease in relation to background statin therapy. Methods A pooled analysis of the randomized ADVANCE, EUROPA, and PROGRESS trials was performed to evaluate CV outcomes in 29,463 pat...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular drugs and therapy 2024-02, Vol.38 (1), p.131-139
Main Authors: Radhoe, S. P., Boersma, E., Bertrand, M., Remme, W., Ferrari, R., Fox, K., MacMahon, S., Chalmers, J., Simoons, M. L., Brugts, J. J.
Format: Article
Language:English
Subjects:
Angiotensin-Converting Enzyme Inhibitors - adverse effects
Beta blockers
Blood pressure
Cardiology
Cardiovascular disease
Cerebral infarction
Cholesterol
Clinical trials
Confidence intervals
Coronary vessels
Diabetes
Drugs
Heart attacks
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects
Hypertension
Ischemia
Medical treatment
Medicine
Medicine & Public Health
Mortality
Myocardial infarction
Original
Original Article
Patients
Perindopril - adverse effects
Placebos
Population studies
Randomization
Regression analysis
Statins
Statistical analysis
Stroke
Stroke - drug therapy
Transient ischemic attack
Treatment Outcome
Vascular diseases
Vein & artery diseases
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To study the effects of a perindopril-based regimen on cardiovascular (CV) outcomes in patients with vascular disease in relation to background statin therapy. Methods A pooled analysis of the randomized ADVANCE, EUROPA, and PROGRESS trials was performed to evaluate CV outcomes in 29,463 patients with vascular disease treated with perindopril-based regimens versus placebo. The primary endpoint was a composite of CV mortality, nonfatal myocardial infarction, and stroke. Multivariable Cox regression analyses were performed to assess the effects of a perindopril-based regimen versus placebo in relation to statin use. Results At randomization, 39.5% of the overall combined study population used statins. After a mean follow-up of 4.0 years (SD 1.0), the cumulative event-free survival was highest in the statin/perindopril group and lowest in the no statin/placebo group (91.2% vs. 85.6%, respectively, log-rank p  
ISSN:0920-3206
1573-7241
DOI:10.1007/s10557-022-07384-2